meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
Tislelizumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs docetaxel
All patients
cell type, non squamous cell
cell type, squamous cell
PD-L1 < 1%
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
objective responses (ORR)
objective responses (ORR) (extension)
PFS (extension)
progression or deaths (PFS)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Acute kidney injury TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Eczema TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Erythema TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Gastrointestinal disorders TRAE (grade 3-4)
Hepatobiliary disorders TRAE (grade 3-4)
Hypersensitivity TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus generalised TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Renal and urinary disorders TRAE (grade 3-4)
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Vitiligo TRAE (grade 3-4)
deaths (OS)
mNSCLC - L2 - all population
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all population
versus docetaxel
nivolumab alone vs. docetaxel
1
certainty unassessable
statistically conclusive
-29%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open